227 related articles for article (PubMed ID: 29108467)
1. SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors.
Dai X; Wang Z; Wei W
Cell Cycle; 2017; 16(24):2326-2329. PubMed ID: 29108467
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
4. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
[TBL] [Abstract][Full Text] [Related]
5. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
6. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract][Full Text] [Related]
7. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
Blee AM; Liu S; Wang L; Huang H
Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
[TBL] [Abstract][Full Text] [Related]
8. Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants.
Ostertag MS; Hutwelker W; Plettenburg O; Sattler M; Popowicz GM
J Mol Biol; 2019 May; 431(11):2213-2221. PubMed ID: 31026449
[TBL] [Abstract][Full Text] [Related]
9. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
11. G3BP1 inhibits Cul3
Mukhopadhyay C; Yang C; Xu L; Liu D; Wang Y; Huang D; Deonarine LD; Cyrta J; Davicioni E; Sboner A; Robinson BD; Chinnaiyan AM; Rubin MA; Barbieri CE; Zhou P
Nat Commun; 2021 Nov; 12(1):6662. PubMed ID: 34795264
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
13. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
Zhang J; Chen M; Zhu Y; Dai X; Dang F; Ren J; Ren S; Shulga YV; Beca F; Gan W; Wu F; Lin YM; Zhou X; DeCaprio JA; Beck AH; Lu KP; Huang J; Zhao C; Sun Y; Gao X; Pandolfi PP; Wei W
Dev Cell; 2019 Feb; 48(3):329-344.e5. PubMed ID: 30595538
[TBL] [Abstract][Full Text] [Related]
14. AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness.
Wang X; Jin J; Wan F; Zhao L; Chu H; Chen C; Liao G; Liu J; Yu Y; Teng H; Fang L; Jiang C; Pan W; Xie X; Li J; Lu X; Jiang X; Ge X; Ye D; Wang P
Dev Cell; 2019 Feb; 48(3):345-360.e7. PubMed ID: 30595535
[TBL] [Abstract][Full Text] [Related]
15. BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells.
Li J; Ma J; Meng G; Lin H; Wu S; Wang J; Luo J; Xu X; Tough D; Lindon M; Rioja I; Zhao J; Mei H; Prinjha R; Zhong Z
Stem Cell Res; 2016 Sep; 17(2):212-221. PubMed ID: 27591477
[TBL] [Abstract][Full Text] [Related]
16. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
17. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
[TBL] [Abstract][Full Text] [Related]
18. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
Lochrin SE; Price DK; Figg WD
Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
[TBL] [Abstract][Full Text] [Related]
19. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
[TBL] [Abstract][Full Text] [Related]
20. Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4.
Atala A
J Urol; 2018 Apr; 199(4):895-896. PubMed ID: 29642362
[No Abstract] [Full Text] [Related]
[Next] [New Search]